<DOC>
	<DOCNO>NCT00032435</DOCNO>
	<brief_summary>The primary objective study test hypothesis administration folate , pyridoxine ( vitamin B6 ) cyanocobalamin ( vitamin B12 ) high dose patient advance chronic renal failure end stage renal disease abnormally high plasma homocysteine level low homocysteine level death rate compare patient receive placebo . The secondary objective test hypothesis intake vitamin compare placebo decrease incidence myocardial infarction , disable stroke , amputation lower extremity , hemodialysis patient , thrombosis vascular access .</brief_summary>
	<brief_title>Homocysteine Study ( HOST )</brief_title>
	<detailed_description>Primary Hypothesis : The primary objective proposal test hypothesis administration folate , pyridoxine ( vitamin B6 ) cyanocobalamin ( vitamin B12 ) high dose patient advance chronic renal failure end-stage renal disease abnormally high plasma homocysteine level low homocysteine level increase survival . Secondary Hypotheses : The secondary objective test hypothesis intake vitamin decrease : 1 ) MI , 2 ) stroke , 3 ) amputation low extremity , 4 ) combination death , MI , stroke amputation lower extremity , 5 ) thrombosis vascular access hemodialysis patient . Primary Outcome : Death Interventions : A treated group receive daily tablet contain 40mg folic acid , 100mg pyridoxine 2mg B12 versus control group receive placebo . Study Abstract : The experimental design prospective , two-arm , randomize , double blind study , stratify medical center whether patient chronic renal failure end-stage renal disease . In arm 1003 patient ingest daily capsule contain either 40mg folic acid , 100mg pyridoxine 2mg vitamin B12 , placebo . We use stratified randomization ensure treatment balance within end-stage renal disease patient chronic renal failure patient . This 6 year study require accrual phase 2 year treatment phase last minimum 4 year . Patients screen plasma homocysteine concentration . They must level least 15 uM/L enrol study . The study nurse evaluate patient 3 month . Thereafter , patient contact phone , mail prefer , 3-month interval coordinator central location . Secondary endpoint event , hospitalization , onset dialysis , death reason exit study record standard form . Plasma homocysteine level obtain 3 month patient . Patients exclude : age le 21 year , expect life span le 6 month , pregnancy , metastatic cancer , AIDS-related infection , end-stage liver disease , vitamin B12 deficiency , treatment methotrexate , anticonvulsant , unreliable likely non-compliant , participation long-term trial , unwilling unable give inform consent . For relative treatment effect 17 % ( reduce 3-year death rate 28 % 23.2 % ) 80 % power , 2006 patient 36 VA medical center require . An abundance publish report show strong correlation homocysteinemia incidence cardiovascular death . Authors paper unanimously recommend study undertaken determine folate , pyridoxine , vitamin B12 low incidence . The study conduct patient chronic renal failure end-stage renal disease whose plasma homocysteine level incidence cardiovascular death disease among high patient population . By screen patient high plasma homocysteine concentration measure level 3 month , able determine hypothetical reduction death cardiovascular event rate associate decrease plasma homocysteine concentration .</detailed_description>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Patients screen plasma homocysteine concentration . They must level least 15 mM/L enrol study . Patients exclude follow criterion : age le 21 year , expect life span le 6 month , pregnancy , metastatic cancer , endstage liver disease , treatment methotrexate , antifolate medication anticonvulsant , unreliable likely noncompliant , participation another longterm trial , unwilling unable give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>folate</keyword>
	<keyword>pyridoxine</keyword>
	<keyword>vitamin B6</keyword>
	<keyword>cyanocobalamin</keyword>
	<keyword>homoc</keyword>
</DOC>